Current through 2024 Regular Session legislation effective June 6, 2024
Section 689.813 - Exemption from drug labeling requirements(1) A requirement that a health care provider who is authorized to prescribe drugs in this state label a drug dispensed by the health care provider with the information described in subsection (2) of this section does not apply to a drug approved by the United States Food and Drug Administration for the reversal of an opioid overdose if the drug is: (a) In the form of a nasal spray; and(b) Personally dispensed by a health care provider described in this subsection at the location of practice of the health care provider.(2) The information described in subsection (1) of this section includes:(a) The name of the patient;(b) The name and address of the dispensing health care provider;(c) The date of dispensing;(d)(A) The name of the drug or, if the dispensed drug does not have a brand name, the generic name of the drug along with the name of the drug distributor or manufacturer;(B) The drug's quantity per unit, unless the drug is a compound; and(C) The directions for the drug's use stated in the prescription;(e) Cautionary statements, if any, as required by law; and(f) When applicable and as determined by the State Board of Pharmacy, an expiration date after which the patient should not use the drug.Added by 2023 Ch. 285, § 2